RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: Correlation with chemotherapeutic response

Gynecologic Oncology

Volumn 94, Issue 1, 2004, Pages 152-160

  Materna, Verena ^a   Pleger, Juliane ^a   Hoffmann, Uwe ^a   Lage, Hermann ^a  

^a Charité Campus Benjamin Franklin Medical Center   (Germany)

Author keywords

DNA topoisomerase I; MDR1 P glycoprotein; Ovarian carcinoma; RNA expression

Indexed keywords

DNA TOPOISOMERASE; GLYCOPROTEIN P; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; RNA;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEASUREMENT; OUTCOMES RESEARCH; OVARY; OVARY CARCINOMA; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; RECURRENT CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; SAMPLE; STANDARD; SURVIVAL TIME;

DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; HUMANS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM STAGING; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 3242663647     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.03.035     Document Type: Article

References (45)

1. Daly M., Obrams G.I. Epidemiology and risk assessment for ovarian cancer. Semin. Oncol. 25:1998;255-264
2. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer statistics 1998. CA Cancer J. Clin. 48:1998;6-29
3. Ozols R.F., Schwartz P.E., Eifel P.J. Ovarian cancer, fallopian tube carcinoma and peritoneal carcinoma. De Vita V.T. Jr., Hellman S., Rosenberg S.A. Cancer: principles and practice of oncology. sixth ed.:2001;1597-1632 Lippincott-Raven, Philadelphia
4. Nooter K., Herweijer H. Multidrug resistance (mdr) genes in human cancer. Br. J. Cancer. 63:1991;663-669
5. Lage H. ABC-transporters: implications on drug resistance from microorganisms to human cancers. Int. J. Antimicrob. Agents. 22:2003;188-199
6. Ambudkar S.V., Kimchi-Sarfaty C., Sauna Z.E., Gottesman M.M. P-glycoprotein: from genomics to mechanism. Oncogene. 22:2003;7468-7485
7. Kruh G.D., Belinsky M.G. The MRP family of drug efflux pumps. Oncogene. 22:2003;7537-7552
8. Taniguchi K., Wada M., Kohno K., Nakamura T., Kawabe T., Kawakami M., et al. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res. 56:1996;4124-4129
9. Kool M., de Haas M., Scheffer G.L., Scheper R.J., van Eijk M.J.T., Juijn J.A., et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 57:1997;3537-3547
10. 2-arrest in melanoma cells resistant to cisplatin. J. Invest. Dermatol. 121:2003;172-176
11. Cui Y., König J., Buchholz U., Spring H., Leier I., Keppler D. Drug resistance and ATP-dependent conjugated transport mediated by the atypical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol. Pharmacol. 55:1999;929-937
12. Wang J.C. Cellular roles of DNA topoisomerases: a molecular perspective. Nat. Rev. Mol. Cell. Biol. 3:2002;430-440
13. Takimoto C.H., Wright J., Arbuck S.G. Clinical applications of the camptothecins. Biochim. Biophys. Acta. 1400:1998;107-119
14. Husain I., Mohler J.L., Seigler H.F., Besterman J.M. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res. 54:1994;539-546
15. McLeod H.L., Douglas F., Oates M., Symonds R.P., Prakash D., van der Zee A.G., et al. Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. Int. J. Cancer. 59:1994;607-611
16. Lynch B.J., Bronstein I.B., Holden J.A. Elevations of DNA topoisomerase I in invasive carcinoma of the breast. Breast J. 7:2001;176-180
17. Kanzawa F., Sugimoto Y., Minato K., Kasahara K., Bungo M., Nakagawa K., et al. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res. 50:1990;5919-5924
18. Siebert P.D., Larrick J.W. Competitive PCR. Nature. 359:1992;557-558
19. Olesen L.H., Norgaard J.M., Pallisgaard N., Bukh A., Hokland P. Validation and clinical implication of a quantitative real-time PCR determination of MDR1 gene expression: comparison with semi-quantitative PCR in 101 patients with acute myeloic leukemia. Eur. J. Haematol. 70:2003;296-303
20. Goerke C., Bayer M.G., Wolz C. Quantification of bacterial transcripts during infection using competitive reverse transcription-PCR (RT-PCR) and LightCycler RT-PCR. Clin. Diagn. Lab. Immunol. 8:2001;279-282
21. Kim Y., Gharaibeh S.M., Stedman N.L., Brown T.P. Comparison and verification of quantitative competitive reverse transcription polymerase chain reaction (QC-RT-PCR) and real time RT-PCR for avian leukosis virus subgroup J. J. Virol. Methods. 102:2002;1-8
22. Wall S.J., Edwards D.R. Quantitative reverse transcription-polymerase chain reaction (RT-PCR): a comparison of primer-dropping, competitive, and real-time RT-PCRs. Anal. Biochem. 300:2002;269-273
23. Nieth C., Priebsch A., Stege A., Lage H. Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett. 545:2003;144-150
24. Bourhis J., Goldstein L.J., Riou G., Pastan I., Gottesman M.M., Benard J. Expression of a human multidrug resistance gene in ovarian carcinomas. Cancer Res. 49:1989;5062-5065
25. Codegoni A.M., Broggini M., Pitelli M.R., Pantarotto M., Torri V., Mangioni C., et al. Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer. Gynecol. Oncol. 65:1997;130-137
26. Noonan K.E., Beck C., Holzmayer T.A., Chin J.E., Wunder J.S., Andrulis I.L., et al. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc. Natl. Acad. Sci. U. S. A. 87:1990;7160-7164
27. Rubin S.C., Finstad C.L., Hoskins W.J., Saigo P.E., Provencher D.M., Federici M.G., et al. Expression of P-glycoprotein in epithelial ovarian cancer: evaluation as a marker of multidrug resistance. Am. J. Obstet. Gynecol. 163:1990;69-73
28. Holzmayer T.A., Hilsenbeck S., Von Hoff D.D., Roninson I.B. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J. Natl. Cancer Inst. 84:1992;1486-1491
29. Baekelandt M.M., Holm R., Nesland J.M., Trope C.G., Kristensen G.B. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. Anticancer Res. 20:2000;1061-1067
30. Joncourt F., Buser K., Altermatt H., Bacchi M., Oberli A., Cerny T. Multiple drug resistance parameter expression in ovarian cancer. Gynecol. Oncol. 70:1998;176-182
31. Izquierdo M.A., van der Zee A.G.J., Vermorken J.B., van der Valk P., Belien J.A.M., Giaccone G., et al. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognosis in advanced ovarian carcinoma. J. Natl. Cancer Inst. 87:1995;1230-1237
32. Arts H.J.G., Katsaros D., de Vries E.G.E., Massobrio M., Genta F., Danese S., et al. Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin. Cancer Res. 5:1999;2798-2805
33. van der Zee A.G.J., Hollema H., de Jong S., Boonstra H., Gouw A., Willemse P.H.B., et al. P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res. 51:1991;5915-5920
34. Arao S., Suwa H., Mandai M., Tashiro H., Miyazaki K., Okamura H., et al. Expression of multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer. Cancer Res. 54:1994;1355-1359
35. van der Zee A.G.J., Hollema H., Suurmeijer A.J.H., Krans M., Sluiter W.J., Willemse P.H.B., et al. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J. Clin. Oncol. 13:1995;70-78
36. Kavallaris M., Leary J.A., Barrett J.A., Friedlander M.L. MDR1 and multidrug resistance-associated protein (MRP) gene expression in epithelial ovarian tumors. Cancer Lett. 102:1996;7-16
37. Lincke C.R., van der Bliek A.M., Schuurhuis G.J., van der Velde-Koerts T., Smit J.J., Borst P. Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr1 complementary DNA. Cancer Res. 50:1990;1779-1785
38. Minemura M., Tanimura H., Tabor E. Overexpression of multidrug resistance gene MDR1 and cMOAT in human hepatocellular carcinoma and hepatoblastoma cell lines. Int. J. Oncol. 15:1999;559-563
39. McLeod H.L., Keith W.N. Variations in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity. Br. J. Cancer. 74:1996;508-512
40. van der Zee A.G.J., de Jong S., Keith W.N., Hollema H., Boonstra H., de Vries E.G.E. Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors. Cancer Res. 54:1994;749-755
41. Cornarotti M., Capranico G., Bohm S., Oriana S., Spatti G.B., Mariani L., et al. Gene expression of the DNA topoisomerase I, II alpha and II beta and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Int. J. Cancer. 67:1996;479-484
42. Holden J.A., Rahn M.P., Jolles C.J., Vorobyev S.V., Bronstein I.B. Immunohistochemical detection of DNA topoisomerase I in formalin fixed, paraffin wax embedded normal tissues and in ovarian carcinomas. Mol. Pathol. 50:1997;247-253
43. Codegoni A.M., Castagna S., Mangioni C., Scovassi A.I., Broggini M., D'Incalci M. DNA-topoisomerase I activity and content in epithelial ovarian cancer. Ann. Oncol. 9:1998;313-319
44. Ohishi Y., Oda Y., Uchiumi T., Kobayashi H., Hirakawa T., Miyamoto S., et al. ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma. Clin. Cancer Res. 8:2002;3767-3775
45. Demeule M., Brossard M., Beliveau R. Cisplatin induces renal expression of P-glycoprotein and canalicular multispecific organic anion transporter. Am. J. Physiol. 277:1999;F832-F840